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Abstract 
 
Breast microcalcifications (MC) are a common mammographic finding. MC are 
considered suspicious signs of breast cancer and a breast biopsy is required, however, 
cancer is diagnosed in only a few patients. Reducing unnecessary biopsies and rapid 
characterization of breast MC are unmet clinical needs. In this study, 473 MC detected on 
breast biopsy specimens from 56 patients were characterized entirely by Raman 
mapping, and confirmed by X-ray scattering.  
MC from malignant samples were generally more homogeneous, more crystalline and 
characterized by a less substituted crystal lattice compared to benign samples. There 
were significant differences in Raman features corresponding to the phosphate and 
carbonate bands between the benign and malignant groups. In addition to the 
heterogeneous composition, the presence of whitlockite specifically emerged as marker of 
benignity in benign MC.  
The whole Raman signature of each MC was then used to build a classification model 
that distinguishes MC according to their overall biochemical composition. After validation, 
MC found in benign and malignant samples were correctly recognized with 93.5% 
sensitivity and 80.6% specificity. Finally, MC identified in malignant biopsies, but located 
outside the lesion, reported as well malignant features in 65% of in situ and 98% of 
invasive cancer cases, respectively, suggesting that the local microenvironment 
influences MC features. This study confirms that the composition and structural features 
of MC correlate with breast pathology, and indicates new diagnostic potentialities based 
on MC assessment. 
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INTRODUCTION 
The clinical presentation of breast cancer has profoundly changed in recent years, thanks 
to the wide adoption of screening mammography. Therefore, a shift toward early breast 
cancer has been observed. In this context, breast microcalcifications (MC) are a common 
finding on mammography and they even increased following the evolution of digital 
imaging techniques, but only a small proportion of them reveals a breast cancer (1,2). 
This results in a positive predictive value (PPV) for biopsy with MC ranging between 20% 
and 40% (3) and it contributes to the overall high false positive rates of mammography, 
accounting for $2.8–4 billion per year in the United States only (4,5). Nowadays, the 
description of MC in clinics is only based on morphological features in mammograms or 
by their general appearance on stained histological samples (6,7). MC are classified as 
Type I and Type II. Type I MC (calcium oxalate, CO) is an uncommon type of mineralized 
component, mainly associated with benign lesions; Type II MC, composed by calcium 
phosphate (mainly by hydroxyapatite (HA)), are the most frequently observed, both in 
benign and malignant samples (6,8). Several computational efforts have been attempted 
to improve the assessment of MC during mammography using deep learning and other 
computer-aided tools (9) but these are not able to discriminant their molecular 
composition. Only recently, a contrast-phase X-ray mammography approach reported the 
possibility to study MC composition and to distinguish Type I and Type II MC (10), but 
what is missing is the assessment of Type II MC malignancy. 
Raman spectroscopy (RS) is a non-destructive approach able to define the biochemical 
composition of samples in label-free (11) and it is particularly adequate to study minerals 
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components in biological samples (12). In addition, RS is compatible with real-time in-vivo 
diagnostic evaluations (13–16). Haka et al. reported for the first time that RS is able to 
recognize biochemical differences between benign and malignant MCs (74 and 16 
calcifications, respectively) by carrying out single acquisitions at selected sites inside the 
calcified lesion (8). Subsequently, Raman-based tools were proposed in order to study 
MC in tissue. Stone, Matousek and collaborators reported both space-offset RS (SORS) 
and transmission-RS approaches potentially able to study MC without penetrate the 
tissue, and tests were performed on phantom samples (17,18). Fitzmaurice, Barman and 
collaborators developed a RS-based optical fiber probe potentially able to investigate MC 
penetrating the tissue in a semi-invasive approach (19,20). The optical probe was tested 
on ex-vivo tissue samples confirming the potentiality of RS-based approaches to assess 
MC. In parallel to RS, Stone and collaborators used infrared spectroscopy on histological 
samples reporting a decrease of carbonate content of HA passing from benign to invasive 
samples (21).  Even considering the mentioned literature, the current knowledge about 
MC composition is still limited. No previous Raman-based studies investigated the 
detailed composition of MC by studying the mineral composition over their entire surface; 
previous RS-based studied considered a relative low number of calcified regions and the 
investigation of MC associated with invasive carcinoma was scarce or absent. Here, we 
report the currently most extended biochemical characterization of breast MC thanks to 
the use of a Raman mapping approach on core biopsies. The aim of the present study is 
to clarify the association between MC composition and the pathological features of breast 
lesions and the surrounding tissue, validating some specific evidences by X-ray scattering 
approaches. Moreover, MC surrounding malignant lesions were investigated to 
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understand the influence of nearby cancerous tissue on their biochemical features. 
 
MATERIALS AND METHODS 
Samples 
Fifty-six patients affected by suspicious breast MC on screening mammography, 
undergoing a core biopsy and treated at the Breast Unit of ICS Maugeri (Pavia, Italy) from 
2018 to 2019, were included. Patients with mass-like lesions or previous breast surgery 
were excluded from the study. All patients signed a written informed consent before 
inclusion in the study, which was authorized by the Ethical Committee of the Institution 
(protocol 2281/2018 CE), which approved the study in compliance with the Declaration of 
Helsinki. In details, according to the B-categories defined by the UK National Health 
Service Breast Screening Program (NHSBSP) (22), 6 patients reported normal tissue or 
minimal changes (B1), 9 patients reported benign lesions (B2), 8 patients reported lesions 
of uncertain malignancy (B3), 17 reported in-situ carcinoma (B5a) and 16 reported 
invasive carcinoma (B5b) (Table 1). Detailed characteristics of patients are reported in 
Table S1.  
Tissue preparation 
Tissue slices were generated from formalin fixed paraffin embedded (FFPE) tissue 
blocks. For each patient, a 10 µm slice was microtomed and mounted on mirrored 
stainless-steel slides specific for Raman measurements (Renishaw plc, Wotton-under-
Edge, UK). In parallel, for each tissue sample, a contiguous 6 µm tissue slice was colored 
using standard hematoxylin eosin stain for standard diagnostic evaluation. To correctly 
assess the concordance of histopathology with specific Raman features, MC located 
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inside in-situ or invasive carcinoma were primarily considered in B5a and B5b samples, 
respectively, and defined among “representative” MC. MC detected in samples reporting 
cancer but locally surrounded by tissue that could be categorized with a lower B-category 
(i.e. non-cancerous tissue in B5a samples and both non-cancerous tissue or in situ 
carcinoma in B5b samples) were analyzed separately. The 10 µm slices selected for 
Raman analyses were then deparaffinized using a simple protocol optimized starting from 
a previously reported method (23). Briefly, tissue slices mounted onto mirrored steel 
slides were dewaxed by two baths of hexane 95% (Merck KGaA, Darmstadt, Germany), 
two baths of ethanol absolute (Merck KGaA, Darmstadt, Germany) and a final bath of 
ethanol 95%, repeating these steps three times, followed by air drying for 2 h.  
Raman spectroscopy 
The experimental and data analysis workflow is illustrated in Figure 1. A commercial 
confocal Raman microscope (InVia Reflex, Renishaw plc, Wotton-under-Edge, UK) was 
used to perform Raman mapping acquisitions. A 785 nm laser source with round shape 
spot, powered with around 90 mW, was coupled with a N-Plan 100x (NA 0.75, WD 0.37) 
Leica objective and with a 1200 l/mm grating, centred around 1250 cm-1 thus obtaining a 
spectral range between 700 and 1760 cm-1. The final power was then filtered to reach 
around 20 mW on the sample. The detector is a CCD (1024x256 pixels) sensitive 
between 400-1060 nm and cooled at -70 °C. The instrument was daily aligned and 
intensity calibrated using automated procedures implemented in the instrument start-up 
process. The wavelength shift calibration was periodically performed using multiple 
standards (polystyrene, paracetamol, silica) and daily checked by an automatic 
procedure using the silica band at 520 cm-1.  
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Raman mapping measurements of each MC identified by the pathologist on the 
contiguous haematoxylin-eosin slice were performed. All MC with diameter between 15 
and 1200 µm were selected. A squared region was centred on each MC defining a step 
size (mapping size) between 1 and 15 µm (on average 6 µm), depending on MC size. 
The focus was pre-set for each MC in the middle of the calcified part. For each step the 
acquisition time was of 3 sec with a single repetition.  
Data processing of Raman data 
Data analysis were performed using the commercial software WiRe (Renishaw plc, 
Wotton-under-Edge, UK) or MATLAB (MathWorks, Natick, MA, USA) or OriginPro2019 
(Originlab Corporation, Wellesley Hills, MA, USA). The data analysis included 1) pre-
processing; 2) spectral classification and 3) statistical/multivariate analysis.  
Data pre-processing started with cosmic rays removal performed by WiRe (nearest 
neighbour and width of features algorithms). Next step was the background correction 
used to reduce fluorescence signals that may compromise the study of Raman spectra.  
Background signal was removed in MATLAB using baseline correction by fitting and 
subtracting a polynomial function of the 10th order to each spectrum. Then, data were 
normalized in MATLAB by unit vector function in order to neutralize spectra intensity 
differences. The normalized data were then filtered with a moving average filter with a 
window size equal to five in order to reduce spectral noise. 
Spectral classification was carried out to assign specific biochemical features (i.e. to 
identify specific components) to each map data point (i.e. for each single spectrum 
acquired). For each spectrum, three different indices (i.e. monotonicity of the spectra, 
correlation with reference spectra and specific peaks positions) were evaluated and used 
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to perform spectral classification (24). Spectra described by a monotonic function are 
those for which the function preserve the given order. Concerning Raman spectra, it is 
known that the fluorescence background is a monotonically decreasing (or increasing) 
function (25). Monotonicity was here mainly used to support the identification of spectra 
with high fluorescence (typical of necrotic regions, see below) and for the identification of 
spectra related to optical support (not monotonic functions). The reference spectra of 
inorganic components (hydroxyapatite (HA), whitlockite (WIT), amorphous calcium 
carbonate (aCaCa), crystalline calcium carbonate (calcite), calcium oxalate (CaO)) are 
reported in Figure 1. Reference spectra were produced by collecting Raman signals 
from real samples and by confirming their nature by X-ray scattering analysis and/or by 
data reported in literature. In details, at least 25 spectra from at least 2 samples were 
recorded and averaged to produce each reference spectrum. For calcium phosphate 
(both HA and WIT), after confirming their nature by data in literature (8,26), 50 µm 
contiguous slices, from the same samples, were studied by X-ray analysis that finally 
confirmed their nature (Figure S1 and Figure S2). For calcium oxalate (CaO), crystalline 
calcium carbonate (calcite) and amorphous calcium carbonate (aCaCa) reference 
spectra were confirmed thanks to available data from literature (from (27) and (8) for 
CaO; from RRUFF id X050034 (28) and from (29) for calcite; from (29) and (30) for 
aCaCa). For these three cases, the scarce number and the small size of MC presenting 
these components did not permit to perform accurate X-ray scattering analysis. Together 
with mineralized components, also references of tissue surrounding MC, necrotic regions 
(presenting typical fluorescence spectra) and stainless-steel microscope slide were 
recorded and used in order to isolate pure signals from the calcified area only. Peak 
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positions, used as third criterion, were extracted, when possible, from above described 
reference spectra. The three mentioned indices were fused with the majority vote system 
in order to produce a thematic (false-colour) map which contains a classification based 
only on spectral information. Spatial classification was taken into account adopting the K-
means clustering algorithm which is specific to detecting the borders (31). The algorithm 
is based on a random initialization of the groups; different executions of this algorithm 
produce different clusters, depending from the initial centroids. Therefore, in order to 
produce reproducible results, the clustering is repeated ten times with different 
initializations. The results of ten clustering phases are then fused together in order to 
obtain a classification false-colour map. The classification map produced by the K-means 
clustering has not a biochemical meaning, since K-means is a non-supervised 
classification method. The biochemical information was obtained by fusing the K-means 
clustering with the spectral classification map produced before. For each K-means 
cluster, the correspondent area was classified by the spectral classification and 
averaged. As result, for each map-dataset (for each MC), each map-point was assigned 
to a specific pre-selected component and, for each component, an average Raman 
signal was produced and extracted. 
Statistical analysis and multivariate analysis were then conducted on the calcified 
components only. If not specified, variables were reported as means (± standard 
deviations) or median with range of values or as absolute numbers and percentages. 
Continuous variables were compared using non-parametric Wilcoxon-Mann-Whitney/ 
Krustal-Wallis test for variables with non-normal distribution. Statistical significance level 
was set at p<0.05 (two tailed). 
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For multivariate analysis, for each MC, a single Raman spectrum, calculated by 
averaging only signals from Type II MC (i.e. HA and WIT components) was than 
considered. Principal component analysis (PCA) was performed obtaining 380 principal 
components (PCs). A linear discriminant analysis (LDA) classification model was built 
using the first fourteen PCs as training data, using pure benign (i.e. B1 and B2 MC) and 
pure malignant (i.e. representative B5a and B5b MC) and setting prior probabilities 
proportional to the group size. The number of PCs to be utilized was selected in order to 
represent about 90% of dataset variability and in order to exclude PCs associated to 
noise and/or small artefacts. The PCA–LDA classification model was validated by the 
leave-one-out cross validation. B3 MC (uncertain malignancy), B5a MC detected outside 
in-situ carcinoma or B5a MC detected outside invasive carcinoma were used as test 
data. ROC curve, with relative AUC, was automatically calculated by OriginLab using as 
input the canonical variable 1 emerging from the PCA-LDA classification. From the ROC 
curve the optimal threshold (cut-off point) was obtained. This was used to produce 
confusion matrices and relative diagnostic performances.  
Small and wide-angle X-ray scattering (SAXS and WAXS), X-ray radiography (XTM) 
The XTM microscopies map more (darker) or less (lighter) X-ray absorbing portions of 
the biopsy; SAXS microscopies display the abundance and D-spacing of collagen; 
WAXS microscopies map the abundance and lattice parameters of the HA structure of 
MC. To confirm the crystal phase composition of MC, 50 μm slices, contiguous to 
samples used for RS, were deparaffinized using the protocol reported above and 
analyzed using XTM, SAXS and WAXS microscopy data were collected at the cSAXS 
beamline of the Swiss Light Source (SLS) in Villigen, Switzerland (32). The 
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monochromatic X-ray beam had a wave-length of 0.091216 nm corresponding to an 
energy of 13.6 keV. It was focused down to about 20 μm (vertical) and 40 μm (horizontal) 
by a bent monochromator crystal and a bent mirror. Sample to detector distances were 
set to 308 mm (WAXS) and 7089 mm (SAXS). Collection time per point was 0.3 s 
(WAXS and SAXS). A Pilatus 2 M detector (33) was used for recording SAXS/WAXS; the 
intensity of the transmitted direct beam was measured by means of  a point detector in 
the beam stop, to obtain the X-ray transmission microscopy (XTM) (radiography). The 
samples were raster-scanned through the focused X-ray beam in a continuous line-scan 
mode, i.e. with the sample moving at constant velocity while the detectors record data at 
constant frequency. The resulting spatial distance between data points of the raster scan 
is 40 μm. Depending on the investigated area, data have been recorded from 6'731 to 
61'875 positions on the sample in each raster scan.  
Data processing - SAXS and WAXS 
The SAXS and WAXS data have been azimuthally integrated within 16 angular sectors. 
The resulting integrated data were screened through a statistical signal classification 
approach (34) to reduce the large number of WAXS and SAXS data to few characteristic 
profiles. The characteristic WAXS profiles were fitted by a whole profile Rietveld 
approach (35) implemented in the FullProf program (36). The crystallographic unit cell 
parameters (a and c), the unit cell volume (V) and the crystalline domain size along 
several crystallographic directions were determined, gaining the trend of these 
parameters for increasing malignancy. For validating the representativeness of the 
characteristic WAXS profiles selected using signal classification, we explored also the 
entire WAXS dataset across all investigated sample areas. For each pixel of the WAXS 
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microscopy, the peak position of the (002) reflection as an isolated single diffraction peak 
was fitted with a Gaussian to extract peak position, amplitude and width, and in this way 
their variations have been mapped across the whole area. Then, we evaluated the mean 
and dispersion of: the c parameter, by means of the Bragg law applied to the peak 
position; the crystalline domain size along the [002] crystallographic direction, extracted 
with the Scherrer formula from the peak width. The statistical evaluation of c value and 
domain size along the [002] direction mapped across the whole area, were found to be 
nicely in agreement with the same values extracted from the Rietveld fitting of the 
characteristic WAXS profiles determined in a signal classification approach. Both the c 
value and the crystalline domain size along the [002] direction were found to increase 
with the malignancy level. 
In case of the SAXS data, the characteristic profiles have been used to define regions of 
interest for an analysis of characteristic peaks in the scattering signal at each point of 
each raster scan (37). In particular, two main peaks were identified and interpreted as the 
6th order of collagen fibers with 63.0nm D-spacing and as the 7th order of collagen fibers 
with 61.8 nm D-spacing. We monitored their variation across the investigated area and 
related them to WAXS and XTM microscopies. 
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RESULTS 
A total of 474 MC from 56 patients were mapped by Raman spectroscopy as above 
described. Out of these, 65 MC were detected in normal tissue (B1), 67 in samples with 
benign lesion (B2), 61 in samples with uncertain malignant features (B3), 97 in samples 
with in situ carcinoma (B5a) and 184 in samples with invasive carcinoma (B5b). (Table 1 
and Table S1). Only 59 and 63 MC derived from pure B5a and B5b, respectively, and 
primarily considered as representative MC. The remaining were locally surrounded by 
tissue categorized within a lower diagnostic category and studied separately.  
 
Benign MC contain specific components and are more heterogeneous than malignant 
ones 
A Raman mapping approach was optimized in order to characterize and automatically 
identify all inorganic components contained in MC at micrometric scale, Figure 1. Out of 
315 representative MC, 273 (86%) contains HA, the most common form of calcium 
phosphate defining Type II MC (Figure 2A). Overall, HA represents also the most 
abundant component (>74%) of MC (Figure 2B). Considering different diagnosis, benign 
calcifications (B1, B2) are more heterogeneous than uncertain malignant (B3) or 
malignant MC (B5a, B5b). In particular, 33 and 40 MC found in B1 and B2 samples, 
respectively, reported spectral features of WIT (38) (Figure 2A,B), a particular 
magnesium-containing crystal phase of calcium phosphate, as also confirmed by wide-
angle X-ray scattering (WAXS) performed on the selected tissue specimens (Figure S2). 
In RS data, WIT was not found as unique inorganic component but always co-localized 
with HA and it constitutes, overall, 2.7% and 6.2% of B1 and B2 MC, respectively. Some 
benign MC (i.e. 7 and 25 MC in B1 and B2 lesion, respectively) also show the presence of 
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a few signals (<2%) of aCaC. In addition, only 14 MC from B1 samples contain CaO as 
sole component (near 100%) and these calcifications correspond to Type I MC. 
Conversely, malignant (B5a, B5b) and B3 lesions, generally exhibit homogeneous MC, 
containing almost only HA, representing ≥97% of their overall composition (Figure 2A, B). 
A single B3 sample MC presented Type I MC (n=3) containing pure CaO. Among the 
whole dataset, a few MC from both benign and malignant samples reported a highly 
crystalline form of calcium carbonate (calcite), never reported before in breast MC and 
apparently not associated with pathology from our data. Finally, 17 MC identified by the 
pathologists did not show any specific signal of mineralized components and were likely 
amorphous material attributable to necrotic regions.  
  
The chemical features of MC are associated with the diagnostic classification 
Type II MC were mainly investigated here considering that Type I MC are uncommon 
presentations, rarely observed in our samples. The mean Raman spectra of Type II MC 
from different diagnostic categories revealed some differences around the major signals; 
in particular, around the 960 cm-1 band, related to calcium phosphate vibrational modes, 
around the 1070-1090 cm-1 band, related to calcium carbonate content, and around the 
1450 cm-1 band, mainly related to protein and lipids (here referred as “organic matrix”) 
content (Figure 3A-F, Figure S3). In details, a broadening of the phosphate band is 
observed in benign samples (Figure 3A,D) and this is mainly associated with a more 
disordered and more substituted phosphate crystal lattice (39,40). The broadening extent 
is similar in normal (B1) and benign (B2) MC (p=0.43) but significantly higher (p=7.90*10-
10) if compared with MC found in lesion of uncertain malignancy (B3), in-situ (B5a) and 
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invasive lesions (B5b). In turn, B3, B5a and B5b exhibit only minor variation of broadening 
values (p = 0.032), with main contribution by differences between B3 and B5b samples (p 
= 0.011) (Table S2). In parallel, observing the phosphate peak, a statistically significant 
shift toward higher wavenumbers (here referred as “red-shift”) is also observed in benign 
MC (p=0.025). This is mainly derived by the presence of WIT in benign MC, characterized 
by maximum intensity of the phosphate band around 970 cm-1 (38) (Figure 3, Figure S4, 
Table S3).  
Also the carbonate band reveals higher intensity and broadening in benign samples in the 
spectral region between 1070-1090 cm-1, showing significant differences when comparing 
benign (B1, B2) and non-benign (B3, B5a, B5b) subtypes (p=2.86*10-9) (Figure 3B,E). No 
significant differences can be observed when comparing B1 and B2 (p = 0.51) and a 
certain variance characterize B3, B5a and B5b (p = 0.001), especially due to differences 
between B5a and B5b (Figure 3B,E). Finally, the intensity of the 1450 cm-1 band, 
corresponding to the organic matrix, also changes among diagnostic categories, but 
differences do not correlate with the pathological status (Figure 3C,F).  
 
The crystalline lattice of MC is more ordered and expands with increasing malignancy  
In order to better understand some biochemical and structural features emerging from 
Raman data, crystallographic evaluations by WAXS were performed on randomly 
selected samples, focusing on Type II MC, and on HA structures. Figure 4A shows the 
HA crystalline domain parameter and the HA crystallographic unit cell “c” parameter 
increasing when passing from benign (B1, B2) to carcinoma samples (B5a, B5b) (overall 
diffractograms in Figure S1). This behaviour is coherent with the broadening of 
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phosphate Raman peak (Figure 4A,B) passing from malignant to benign samples. Both 
these data indicate that the crystallinity and homogeneity of HA produced by malignant 
MC is significantly higher if compared with benign samples. In particular, the increasing of 
the “c” parameter indicates that the unit-cell of HA in MC in malignant samples is 
generally elongated in comparison to the one in benign samples. 
Finally, SAXS data show that collagen is co-located with MC and that it has longer inter-
molecular D-spacing of 63.0 nm in comparison to 61.8 nm of collagen found outside the 
MC (Figure S5, S6). These findings reveal that HA nanocrystals are spatially correlated 
to the larger D-spacing of the collagen fibres, which can be interpreted as a hint towards 
crystallization nucleating on collagen fibres. A weak tendency towards an overall increase 
of the intramolecular spacing of collagen is found passing from benign to malignant MC 
(Figure S6) and this is interpreted speculatively as a tighter binding of collagen to 
malignant MC. 
 
The multivariate analysis of MC Raman maps allows for the accurate classification of 
different histological subtypes 
Multivariate analysis was applied to extract all potential pathological biomarkers from the 
complexity of Raman data thus improving the limited and subjective analysis of single 
spectrometric variables. First, principal component analysis (PCA) was performed and the 
first fourteen principal components (Figure S7), representing 90% of the variability of the 
entire dataset, were extracted and used as variables for further classification. A 
classification model was made by LDA firstly using only representative MC from pure 
benign samples (i.e. B1 and B2) and from pure malignant samples (B5a and B5b) thus 
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producing a Raman canonical correlation coefficient (canonical variable 1) further used as 
unique classification variable (Figure 5A-C). After excluding a correlation between age 
and the biochemical composition of MC (R2=0.020, slope p =0.33) (Figure S8), a receiver 
operating characteristic (ROC) curve (Figure 6) was calculated and used to find the 
optimal threshold point (i.e. -0.445 of canonical variable) for the classification. Out of 108 
malignant MC, 103 were correctly classified giving 95.4% sensitivity and 94.6% negative 
predictive value (NPV) (Table S4). Among MC incorrectly assigned as benign, 4 were 
from ductal carcinoma in situ (DCIS), 1 from invasive ductal carcinoma (IDC). Out of 103 
benign MC, 15 were wrongly assigned as malignant giving 85.4% of specificity and 87.3% 
PPV. Out of benign MC wrongly classified as malignant 10 were from normal tissue, 1 
from fibroadenoma (FAD), 2 from fibrocystic change (FIB), 2 from usual ductal 
hyperplasia (UDH). Overall, the model gives 90.5% accuracy. These results were 
validated through leave-one-out cross validation which virtually assigns all MC with an 
unknown diagnosis before to be classified. This gave 93.5% sensitivity and 80.6% 
specificity with 87.2% of overall accuracy (Table S5).  
The classification model was then used to investigate the pathological fingerprint of MC 
found in lesion of uncertain malignancy (B3). Out of 53 B3 MC, 44 (29 from flat epithelial 
atypia tissue and 15 from ADH) were assigned as malignant and 9 MC (7 ADH, 1 flat 
epithelial atypia and 1 from papillary lesion) were recognized as having benign features 
(Figure 5B, Table S6). Moreover, also a correlation between the Raman data and 
mammographic evaluation according to the Breast Imaging-Reporting and Data System 
(BI-RADS) (26) classification was observed (Figure S9). Finally, considering that MC size 
can be very heterogeneous, as showed in Figure S10 (mean: 14511 µm2; SD: 27229 
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µm2; IQR 25-75%: 11700 µm2), the correlation between MC size and malignant features, 
as revealed by Raman mapping (i.e. Canonical variable 1), has been investigated 
showing a weak correlation (-0,1894; p = 0.0002 (Spearman’s correlation)),  suggesting 
that larger MC are slightly associated with lower malignancy.  
 
Most of MC found in locally healthy tissue neighbouring carcinoma lesions show 
malignant features  
116 MC (28 and 88 for B5a and B5b, respectively) were excluded from the main data 
analysis because locally surrounded by non-cancerous tissue in B5a samples, or because 
surrounded by non-cancerous tissue or in-situ carcinoma in B5b samples. When data 
from B5a samples were used as test dataset, out of 28 MC found locally benign, 18 
showed malignant features and were classified as malignant, the remaining 10 MC were 
classified as benign (Figure 5C, Table S6). Out of 88 MC from B5b detected outside the 
invasive carcinoma, only 2 MC (locally B1) were classified as benign but the remaining 80 
were classified as malignant (Figure 5C, Table S6). These include 29 MC situated in in-
situ carcinoma (B5a), 23 MC surrounded by B3 tissue, but also 34 MC surrounded by B1 
tissue.  
  
Research. 
on February 27, 2020. © 2020 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 24, 2020; DOI: 10.1158/0008-5472.CAN-19-3204 
19  
DISCUSSION 
The rapid and accurate characterization of breast MC is currently an unmet clinical need. 
MC are considered as suspicious signs of a breast lesion, and histopathology is 
mandatory to assess the nature of such lesions. Up to now, MC have been traditionally 
seen by mammography as simple bystanders of cancer and only characterized by 
descriptive criteria (i.e. morphology and spatial distribution), according to the Breast 
Imaging-Reporting and Data System (BI-RADS) (41). Recently, research teams have 
begun to show the potential of further spectral analysis using Raman and IR spectroscopy 
(8,17,21,40,42), but this paper advances the concept significantly. 
Here we investigated breast MC from different diagnostic categories by studying the 
whole area of each MC using a Raman mapping approach on a relevant number of MC. 
This allowed for the first time to describe all inorganic components contained in MC and to 
correlate it with the pathological status. Previously reported Raman characterizations 
have been made on a significantly lower number of MC and by performing single 
acquisitions at selected sites inside the calcified lesion (8) or single spectra on fresh 
biopsies (40), thus obtaining partial information. Only recently the spatial composition of 
MC has been investigated by Raman mapping on the whole MC surface, although on a 
single DCIS specimen, with explorative aims (26).  
The first evidence emerging from this study is that MC from pure benign lesions (i.e. B1 
and B2) are largely heterogeneous if compared with both lesions of uncertain malignant 
potential (B3) and with carcinoma lesions (B5a, B5b). First, in benign samples both Type I 
(calcium oxalate) and Type II (hydroxyapatite) MC were observed, confirming what 
previously reported; also confirming that Type I MC are uncommon findings (8). Second, 
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in most of Type II MC identified in benign samples, hydroxyapatite is not the only 
component but also whitlockite and aCaCa were observed, (in 55% and 24% of benign 
MC, respectively). Whitlockite is a crystal phase of calcium phosphate, sporadically 
detected in human tissues where magnesium partially substitutes calcium if compared 
with hydroxyapatite (43). In this study, investigating 56 sample and 315 representative 
MC, whitlockite overall represents 4.5% of benign calcifications (B1, B2), 0.32% of B3 
samples, and the 0.22% of cancerous calcification (B5a, B5b). These results were further 
confirmed when the mean spectrum of each MC was considered. Recently, whitlockite 
was identified by X-ray in a previous study reporting more whitlockite in malignant (1.18%) 
then in benign (0.46%) samples (44). This discrepancy could be explained by a lower 
number of samples (57 MC from 15 biopsies) included in the mentioned study and by the 
lower spatial resolution of X-ray measures (10 µm), if compared with an average mapping 
size of 6 µm used here for Raman mapping.  
In parallel, the finding of both amorphous (aCaCa) and crystalline calcium carbonate 
(calcite) as isolated components in MC is a new evidence. aCaCa was mostly found in 
benign samples, always localized with whitlockite, and this could be due to the fact that 
magnesium, contained in whitlockite, is known to stabilize aCaCa (45). Calcite is the 
stable and crystalline form of CaCa that can naturally form if not stabilized by active 
processes (46) and has been find in both benign and malignant samples only as single 
very small crystals of pure calcite. The amount of data is not sufficient to explain an 
association with pathology. 
When the overall Raman signals originating from single Type II MC were extracted to 
verify their correlation with diagnosis, the first evident feature was the broadening and 
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red-shift of the 960cm-1 phosphate band of calcium phosphate in B1 and B2 samples. The 
broadening of the phosphate band is normally explained by the increase of carbonate 
content into hydroxyapatite, resulting in the alteration of the symmetry of the crystal 
structure (39). The red-shift of the phosphate band is due to the change of the crystal 
composition as in the case of whitlockite, due to the presence of magnesium (38). In our 
data, both contributions have been seen and this is explained by the co-presence of 
(carbonated) apatite and of whitlockite in benign MC. Previous RS studies on real 
samples, only mentioned peak broadening and this could be due to single point 
acquisition, not able to recapitulate the whole MC composition (8,40). Noteworthy, when 
960 cm-1 peak broadening (FWHM) is compared among diagnostic categories, B3, B5a 
and B5b samples cluster together with only minor differences (p = 0.032). In parallel, also 
the band of carbonate changes among diagnostic categories, decreasing in its overall 
intensity passing from benign to malignant samples. Also in this case, there is a possible 
contribution derived by the presence of whitlockite in benign samples, producing band 
broadening and a weak shoulder at higher Raman shift, and this was not revealed in 
previous studies describing carbonate as indicator of benignity (8,21,40). As a final point, 
organic matrix (i.e. proteins and lipids) has been described as MC component but its 
contribution did not show any statistically significant correlation with pathology as 
previously reported (8,40).   
Spectral data were also confirmed by WAXS acquisitions on randomly selected samples, 
showing that malignant samples (B5a and B5b) exhibit an increase of crystallinity, in 
accordance with previous findings (44). In connection to the observation in RS that WIT is 
more abundant in benign than in malignant MC, one could speculate that malignant MC 
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contain less Mg, thus exhibiting a more well-ordered HA crystalline lattice. In healthy 
conditions, biomineralization involves hydroxyapatite with partial substitution of Ca ions 
(47). Smaller cations, such as Mg ions, lead to a cell contraction compared to the 
stoichiometric crystal (48). Therefore, the observed trend of the “c” parameter can be 
correlated to an altered metabolism of Mg ions, which changes with the malignancy level. 
Indeed, neoplastic cells, i.e. for B5 samples, are avid of Mg cations (49), which therefore 
might reduce the Mg quantity available for MC, justifying the lattice expansion, compared 
to what expected in benign biomineralization. In addition, the observed trend of the “c” 
parameter, which increases passing from benign to malignant MC, may be also 
associated with carbonate substitution in HA structures (50). This is coherent with 
relatively higher levels of carbonate Raman signals in benign samples, reported in this 
and in previous studies (21,40). In particular, lowering of the “c” parameter occurs when 
carbonate mainly substitutes the hydroxyl site of HA (called “A-Type substitution”) and this 
has also been observed in a very recent X-ray diffraction study on MC (51). SAXS data 
exhibit slightly larger D-spacing of collagen in MC found in malignant samples compared 
to benign ones, in agreement with SAXS data collected on tissue (52). This weak trend 
can be speculatively attributed to a tighter binding of MC to collagen with increasing 
malignancy.  
A general overview of results coming from the detailed characterization of breast MC 
suggests that malignant microcalcifications are more homogeneous, more crystalline, less 
substituted (by Mg and carbonate) and more tightly bound to collagen, if compared with 
benign ones. In addition, chemical and structural MC from lesion of uncertain malignancy 
(B3), are general similar to pure malignant ones (B5a and B5b). Studies performed on 
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tissue samples and in vitro on cultured cells demonstrated that MC formation is a cell-
active process influenced by the microenvironment and by the overexpression of bone 
matrix proteins (i.e. osteonectin (OSN) and osteopontin (OPN)) (53,54). Both these 
studies reported that active processes of MC formation are significantly more represented 
in case of malignancy. In parallel, a retrospective study on patients referred for needle-
guided biopsy, reported that the formation of new MC significantly correlates with high 
probability of ductal invasive carcinoma (55). These data suggest that malignant lesions 
are more active in the formation of MC. In this regard, we have seen a weak correlation 
between MC size and malignancy features indicating that, smaller MC are lightly 
associated with higher malignancy. This could be speculatively associated with the 
smaller size of new forming MC during carcinoma growth. Starting from these 
assumptions, the crystallinity and homogeneity of malignant MC could originate from a 
faster and active process stimulated by cancer and by its microenvironment. On the 
contrary, the heterogeneity and low crystallinity of benign MC could be explained by a 
slower and less regulated mechanism of mineralization, thus permitting both loss of 
crystal stability and/or the intercalation of external components (i.e. carbonate, 
magnesium) from the surrounding tissue.  
In order to verify the accuracy of the presented Raman-based MC characterization, a 
multivariate approach was applied, including the use of a LDA-based model to 
automatically verify the potential diagnostic performance of the proposed approach. The 
model was built using pure benign (B1, B2) and pure malignant (B5a, B5b) categories; 
including only MC detected inside carcinoma region in case of malignant MC. The results 
are promising, showing 93.5% sensitivity and 80.6% specificity with an NPV of 92.2% 
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after cross-validation. The same classification model was used to investigate the grade of 
malignancy of B3, according to the biochemical composition, revealing that 39 (83%) of 
53 B3 MC detected show malignant features, mostly by FEA subtype. This data is in 
agreement with the fact that FEA represents a direct pre-cancerous lesion possibly 
leading to DCIS in up to 18.6% of cases (56).  
In addition, we investigated whether all MC detected in malignant biopsy samples, but 
outsides the specific cancer lesion, exhibit the features of the local “benign” (or B3 or 
DCIS) surrounding tissue, or the malignant features of the carcinoma nearby. As 
described above, 64% of locally benign (or B3) MC found around DCIS samples showed 
malignant features. In invasive carcinoma samples, 86 (98%) of 88 MC found outside the 
invasive region (including 34 (94%) of 36 locally classified as B1) were classified as 
malignant. This is interesting data showing that the biochemical composition and 
structural features of MC are influenced by the tumour even if MC are not directly 
surrounded or in close contact with cancer cells. As a consequence we can assume that 
the tumour environment, and probably the metabolism of breast tissue in the presence of 
malignancy (especially if invasive carcinoma), influence a relatively extended tissue 
region around the malignancy, as also recently suggested (57). This evidence may also 
help the translation of Raman-based optical probes or Raman-based non-invasive tools 
potentially compatible with in vivo approaches (17,19,58). In particular, these data 
suggest that the investigation of a relatively large region (500-2000 µm) of suspected 
tissue containing MC could correctly inform about the malignancy even if some locally 
benign MC regions surrounding the lesion are inevitably probed due to low-resolution of in 
vivo configuration. 
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In conclusion, the present study reports new detailed information about MC composition 
and demonstrats that Raman-based approaches can provide a direct and reliable 
description of breast lesions thanks to the study of MC. These evidences may play an 
important role in the development of new tools for the assessment of suspected lesions 
presenting MC. For example, SORS and transmission-Raman approaches are able to 
illuminate a circumscribed portion of sample at a certain depth in a non-invasive manner 
and they were already tested on phantom samples containing calcified components 
(17,58). Similarly, Raman needle probes are able to perform accurate measurements into 
the tissue in a semi-invasive modality (15,16) and a proof-of-concept was also tested to 
study breast MC ex-vivo (19,42). Moreover, preliminary experiments using phase-contrast 
X-ray imaging approaches demonstrated the possibility to study the crystalline structure of 
MC (10). The mentioned tools have not yet been tested or transferred in clinics also due 
to the lack of detailed information about MC composition. The data reported here may be 
step forward to this direction.  
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TABLES 
Table 1. Number of MC detected from different subjects. Samples were classified 
according to the B-categories defined by the UK National Health Service Breast 
Screening Programme (NHSBSP) (22) and according to histological classification. “MC 
outside the lesion” were MC detected in the tissue surrounding B5a or B5b lesions and 
categorized with a lower diagnostic malignancy. “Representative MC” were MC detected 
inside the malignant lesion specified by the diagnostic category (B5a or B5b). 
 
 B Category 
Histological 
classification 
Patients Total MC 
MC found 
outside the 
lesion 
Representative 
MC 
      
B1 “normal tissue” NOR 6 65 - 65 
Total   6 65 - 65 
B2 “benign” 
FAD 4 30 - 30 
FIB 2 8 - 8 
FNE 1 11 - 11 
UDH 2 18  18 
Total   9 67 - 67 
B3 “of uncertain malignancy” 
PAP 2 2 - 2 
FEA (DIN1A) 2 32 - 32 
ADH (DIN1B) 4 27 - 27 
Total   8 61 - 61 
B5a “carcinoma in situ” 
DCIS DIN1C 3 19 11 8 
DCIS DIN2 8 32 8 24 
DCIS DIN3 6 46 19 27 
Total   17 97 38 59 
B5b “invasive carcinoma” 
IDC G2 12 133 92 41 
IDC G3 1 2 2 0 
ILC G2 1 8 8 0 
ILC G3 1 33 19 14 
IMC 1 8 0 8 
Total   16 184 121 63 
Grand Total   56 474 159 315 
 
Abbreviations: normal tissue (NOR); fibroadenoma (FAD); fibrocystic change (FIB); fat necrosis (FNE); usual ductal 
hyperplasia (UDH); papillary lesion (PAP); flat epithelial atypia (FEA); atypical ductal hyperplasia (ADH); ductal 
carcinoma in situ (DCIS); invasive ductal carcinoma (IDC); invasive lobular carcinoma (ILC); invasive mucinous 
carcinoma (IMC).  
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FIGURE LEGENDS 
 
Figure 1. Experimental workflow and components. Overview of the experimental workflow 
(left) and components detected in each Raman map and considered in this study (right). 
The Raman map reported as example was obtained from the analysis of a B5a samples 
and reports the only presence of HA (green), surrounded by tissue (gray).  
 
Figure 2. Detailed composition of representative MC (n=315). A, Number of MC 
exhibiting at least one pixel of the components described by the legend, for each 
diagnostic category. B, Overall composition of MC, calculated considering altogether all 
MC belonging to each diagnostic category. Components: calcium phosphate in the 
hydroxyapatite form (HA), calcium phosphate in the whitlockite form (WIT); amorphous 
calcium carbonate (aCaC); crystalline calcium carbonate (calcite); calcium oxalate (CaO); 
MC not showing specific Raman spectra associated to mineralized components (none).  
 
Figure 3. Vibrational features of representative Type I MC (n=264). Average phosphate 
band (A), average carbonate band (B) and average organic matrix band (C) of each of 
the diagnostic categories, including standard deviation (shaded area). In A, the intensity 
of spectra is shifted for clarity. D, box-plot reporting the broadening (FWHM) of the 
phosphate band. E, box-plot reporting the intensity (area) of the carbonate band, between 
1070-1090 cm-1. F, box-plot reporting the intensity (area) of organic matrix band, between 
1425-1475 cm-1. Data are shown as box ad whiskers. Each data point represents a single 
MC. Each box represents the 25th to 75th percentiles (interquartile range [IQR]). Dots 
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inside the box is the mean, lines inside the boxes represent the median. The whiskers 
represent the lowest and highest values within the boxes ±1.5x the IQR. All p values are 
reported in Table S2. “n.s.” means that not significant difference was observed (p > 0.05 
(two tailed)). 
 
Figure 4. Crystalline feature of HA from selected representative samples. A, Variation of 
the crystalline domain size along the [002] direction. B, Variation of the crystallographic 
unit cell parameter c along the [002] direction. Filled circle represent results of Rietveld fits 
of the few patterns extracted from the entire dataset by a statistical signal classification 
approach (32); empty circles represent the main value resulting from a single-peak fit of 
the (002) reflection at 2=15.29 deg for all the patterns collected in the entire explored 
sample area of a sample. (The analysis reported in Fig. S2 is not included in these trends 
as the sample was a mixture of two crystalline phases, i.e. HA and WIT.) 
 
Figure 5. Results from the LDA-classification model. A, box-plot showing the canonical 
variable score emerging from the LDA-based classification of MC from pure benign (B1, 
B2) and pure malignant (B5a, B5b) samples (n=211). B, box plot reporting the canonical 
variable score of MC found in B3 samples and used as test dataset (n=53). C, box plot 
reporting the canonical variable score of MC found outside carcinoma lesions in B5a 
(n=28) and B5b samples (n=88), used as test dataset.. Data are shown as box ad 
whiskers. Each data point represents a single MC. Each box represents the 25th to 75th 
percentiles (interquartile range [IQR]). Dots inside the box is the mean, lines inside the 
boxes represent the median. The whiskers represent the lowest and highest values within 
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the boxes ±1.5x the IQR. The dashed lines refer to the optimal cut-off value (-0.445) 
defined by the ROC. 
 
Figure 6: ROC curve. The curve was obtained from the post probability assignment 
produced by the LDA-based classification model and considering only pure benign 
(B1,B2) and pure malignant MC (B5a,B5b) (n=211). 
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